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ABSTRACT
Labial salivary gland (LSG) biopsy is used in the
classiﬁcation of primary Sjögren’s syndrome (PSS) and in
patient stratiﬁcation in clinical trials. It may also function
as a biomarker. The acquisition of tissue and histological
interpretation is variable and needs to be standardised
for use in clinical trials. A modiﬁed European League
Against Rheumatism consensus guideline development
strategy was used. The steering committee of the ad hoc
working group identiﬁed key outstanding points of
variability in LSG acquisition and analysis. A 2-day
workshop was held to develop consensus where possible
and identify points where further discussion/data was
needed. These points were reviewed by a subgroup of
experts on PSS histopathology and then circulated via an
online survey to 50 stakeholder experts consisting of
rheumatologists, histopathologists and oral medicine
specialists, to assess level of agreement (0–10 scale)
and comments. Criteria for agreement were a mean
score ≥6/10 and 75% of respondents scoring ≥6/10.
Thirty-nine (78%) experts responded and 16 points met
criteria for agreement. These points are focused on
tissue requirements, identiﬁcation of the characteristic
focal lymphocytic sialadenitis, calculation of the focus
score, identiﬁcation of germinal centres, assessment of
the area of leucocyte inﬁltration, reporting standards and
use of prestudy samples for clinical trials. We provide
standardised consensus guidance for the use of labial
salivary gland histopathology in the classiﬁcation of PSS
and in clinical trials and identify areas where further
research is required to achieve evidence-based
consensus.
INTRODUCTION
Labial salivary gland (LSG) biopsy is widely used in
the diagnosis of primary Sjögren’s syndrome (PSS)
and plays an integral role in the established
American-European Consensus Group classiﬁcation
criteria1 and the proposed American College of
Rheumatology/European League Against
Rheumatism (ACR/EULAR) criteria.2 Evidence sug-
gests that it has the potential to stratify patients,3–6
and may have potential as a biomarker in clinical
trials.7
The most characteristic feature of PSS on biopsy
with a sensitivity and speciﬁcity of >80%8 is focal
lymphocytic sialadenitis (FLS), which describes the
presence of dense aggregates (foci) of ≥50 mono-
nuclear cells (mostly lymphocytes), in a periductal
or perivascular localisation.9 A modiﬁcation based
on focus score (FS) calculation was proposed in
1974,10 and further work established FS ≥1 (ie, ≥1
focus per 4 mm2) for use in classiﬁcation cri-
teria.8 11–14 The Sjögren’s International Clinical
Collaborative Alliance (SICCA) have published a
widely used protocol for sample preparation and
the assessment of FS in suspected Sjögren’s syn-
drome .14 15 Nevertheless, the initial determination
of FLS, prior to calculation of a FS, is still a cause
of variability of practice in the SS community.7 We
previously discussed additional areas of variability
including the acquisition and processing of the sal-
ivary gland tissue and the histological interpretation
of the local inﬁltrate.7 16–18 The SICCA protocol
speciﬁes that foci in FLS occur adjacent to normal
appearing acini, but features of non-speciﬁc chronic
sialadenitis (NSCS) such as atrophy and duct dila-
tion are common in the population and so may
coexist with PSS. NSCS may also be associated
with inﬁltration of lymphocytes and even aggrega-
tion, thus raising issues for interpretation and FS
calculation.7 16 The SICCA protocol provides no
additional guidance beyond FS calculation on the
reporting of size of foci, their degree of organisa-
tion, germinal centres (GCs) and lymphoepithelial
lesions (LESA), the latter being characterised by
lymphocytic inﬁltration of ducts and basal cell
hyperplasia resulting in a multilayered epithelium,
and which may also have prognostic signiﬁcance.19
The goal of this study was to develop a process
of standardisation in order to conﬁrm areas of con-
sensus and highlight areas of uncertainty, with a
view to stimulating further research and evidence-
based recommendations. A few centres use parotid
gland biopsies6 but we have focused this work on
LSG tissue, as this remains the most commonly
employed in clinical practice.20 In this study, we do
not address the biopsy procedure itself but focus on
the processing of the tissue and measurement of
PSS-related inﬂammation. The target users include
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histopathologists, rheumatologists, oral medicine and oral and
maxillofacial surgeons and ophthalmologists, as well as pharma-
ceutical companies planning clinical trials in PSS.
METHODS
The standard operating procedures produced by EULAR on
guidelines development in rheumatic and musculoskeletal disor-
ders broadly formed the basis of the process followed.21
Item development
A literature review was carried out by the steering committee
members of the ad hoc working group. This has been published
and identiﬁed points of outstanding uncertainty for discussion.7
These comprised the agenda items for the workshop.
Workshop
A 2-day workshop was held in February 2014 in Birmingham,
UK.
Day 1
The ﬁrst day focused on histopathology in the diagnosis of PSS.
Presentations addressed the rationale for biopsy, histological fea-
tures and scoring systems, challenges and variability in applica-
tion of the SICCA protocol, GCs and LESA, and methods for
measuring change in biopsies in clinical trials as a prelude for
day 2. There were 23 clinical expert attendees with a back-
ground in rheumatology, histopathology or oral medicine. The
relevant issues were interactively discussed to establish a draft
framework of points to consider in the areas of (1) glandular
tissue requirements, (2) criteria deﬁning FLS and FS and (3)
assessment of GCs and LESAs.
Day 2
A larger number of attendees were present on the second day
(n=39), representing an increased number of specialists with an
interest in PSS clinical trials and including a clinical trials statisti-
cian, a health psychologist and three patient partners.
Presentations summarised issues around the scoring of biopsies,
additional pathological features that may be relevant to clinical
trials and the natural history and reliability of histopathological
changes. Breakout groups and roundtable discussion were used
to propose points relevant to clinical trials in the areas of (1)
calculation of focus size, (2) additional parameters that could be
measured, (3) reporting standards and (4) timing of biopsy and
requirement for a placebo group. In a parallel session facilitated
by a health psychologist, the patient partners discussed the
acceptability of LSG biopsies as a clinical trials outcome
measure. A concluding discussion addressed the agenda for
future work.
Delphi process
The provisional points gathered at the workshop were substi-
tuted for a traditional ﬁrst round of a Delphi process.22 These
were reviewed and edited for clarity and completeness by a sub-
group of six experts. A subsequent eDelphi round was con-
ducted with 50 experts (comprising the original workshop
attendees together with additional experts). These were asked to
rate 20 points on a 0–10 scale, where 0 indicated no agreement
and 10 complete agreement, and to provide explanation when
there was disagreement. Points were divided into those of
general application, and those most relevant to a clinical trials
setting. Explanatory text and selected references accompanied
the points.
Analysis
All the points were graded, based on available evidence, accord-
ing to the scale (A–D) recommended by the Oxford Centre for
Evidence-based Medicine.23 The available evidence has been
previously reviewed.7 Agreement was deﬁned as a mean score of
≥6 and ≥75% of respondents scoring ≥6.
RESULTS
A total of 39 experts (78%) responded to the eDelphi exercise,
of which 22 identiﬁed their principal specialty as rheumatology/
internal medicine (54%), 11 as oral medicine (30%) and 6
(16%) as histopathology. Nine rheumatologists (41%) and four
(36%) oral medicine specialists described their experience of
actually reviewing LSG histopathology as moderate, 8 (36%)
and 2 (18%) as extensive. No discrepancy in responses was
noted between specialty groups. Following the eDelphi exercise,
a total of 16 points (table 1) met the criteria for agreement.
These are listed in table 1, together with the strength of recom-
mendations, and expert scores. The spread of scores is illu-
strated in ﬁgure 1. These points are discussed below. Points not
meeting criteria for agreement are listed in online
supplementary table S1.
Glandular tissue requirements
Given the scattered nature of foci, it is important that there is
sufﬁcient material available to allow a robust and reliable ana-
lysis. In point 1 (table 1), we propose obtaining a minimum of
four LSGs, unless these are small (<2 mm), in which case six
glands should be obtained if feasible. Three respondents argued
for the use of fewer glands (two to three), and two for a greater
number (ﬁve to seven).
A minimum glandular surface area to be examined of 8 mm2
was proposed to facilitate agreement. This minimum should
comprise good quality glandular tissue. In the case of an incon-
clusive biopsy, for example, uncertainty over FLS, borderline FS
for diagnosis or insufﬁcient surface area, then two additional
cutting levels could be employed (point 3). Glandular surface
area from a single cutting level of multiple glands may also be
optimised by aligning glands during preparation of the parafﬁn
blocks (point 4).
Assessment of FLS and FS
The presence of FLS should be determined prior to FS calcula-
tion (point 5) (ﬁgure 2).14 Foci may be conﬂuent and foci of
any size may include plasma cells, although there was some
divergence of expert opinion regarding the extent of plasma cell
inﬁltration that is compatible with FLS. FLS cannot be attribu-
ted when the histological appearance of the glands is dominated
by features associated with NSCS, such as acinar atrophy, duct
dilation and ﬁbrosis, with no evidence of any foci being adjacent
to normal parenchyma. Conversely, given the prevalence of
NSCS, some foci in PSS may be expected to be adjacent to atro-
phic features. Expert recommendation is that the extent of the
atrophic features should be graded and reported to aid the refer-
ring clinician in their interpretation (point 6).
In order to calculate the FS, the total number of foci in the
specimen is divided by the glandular surface area, and multi-
plied by 4, to give the number of foci per 4 mm2 (ﬁgure 2)
Above a FS of 10, foci are typically conﬂuent, and a ‘ceiling’
score of 12 may be applied. Glandular area can be measured
with a calibrated eyepiece grid,15 but measurement-validated
microscope-associated software may also be employed (ﬁgure
2B). An important decision is whether to include apparent foci
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in areas of atrophy, duct dilation and ﬁbrosis, and whether to
include the background area in the glandular surface area
denominator. Different approaches include excluding inﬁltrate
in compact ﬁbrosis but including that around abnormal acini
and ducts, excluding all foci and abnormal areas from the
numerator and denominator, or including all. This decision will
have an impact on the calculated FS.16 There was agreement
that FS calculation should include the whole of the glandular
surface area in the denominator, including abnormal areas, to
avoid introduction of bias (point 7; ﬁgure 2B). This includes
areas of ﬁbrosis, which cannot reliably be removed from the
glandular surface area denominator, although their inclusion
may have the potential to reduce the FS, meaning that some
patients with a FS ≥1 may become <1 at a late stage of disease
(ﬁgure 2C).24 There was also agreement that in the case of PSS
clinical trials at least, the least biased approach and the one
likely to have the greatest reproducibility, would be to assume
all foci are PSS-related and to be included in the FS (point 10).
In the case of repeated biopsies, the patients themselves serve as
an internal control. Arguably, this could also be applied to clin-
ical diagnosis, once the presence of FLS has been determined.
Calculation of focus area
There was support for using the area of mononuclear cell inﬁl-
tration in addition to the FS as a biomarker in clinical trials
(point 9). Data can be presented as percentage of total area inﬁl-
trated and mean focus size. This could be achieved with digital
analysis of H&E or CD45 immunostaining.
Ectopic GCs and LESAs
There was strong agreement that the presence of GCs should be
reported in routine practice (point 8). However, some respon-
dents commented on the need for a clear deﬁnition of these
structures. H&E is considered sufﬁcient to allow accurate detec-
tion of a fully formed GC by a histopathologist, although
additional staining can be used such as B-cell lymphoma 6
(BCL-6) and CD21.
In the context of clinical trials, we have suggested additional
staining with CD21, a marker of follicular dendritic cells
(FDCs) and CD3 and CD20 to better deﬁne the presence of
GCs (point 11) (ﬁgure 3). While CD21 long isoform staining
by itself does not indicate the presence of a GC, the presence of
a FDC network together with B-cell and T-cell segregation
Table 1 Consensus guidance divided into points of general application and those more relevant to clinical trials, showing strength of
recommendation (A–D) based on available evidence, according to the scale (A–D) recommended by the Oxford Centre for Evidence-based
Medicine23
Point
Strength of
recommendation
Number of
respondents
Mean score
(SD) % ≥6
General guidance
1 The minimum number of minor salivary glands is suggested to be four (six if small), and should be
surgically separated
D 39 8.0 (2.4) 82
2 The minimum surface area of gland sections examined should be 8 mm2 D 39 7.5 (1.9) 82
3 If the first cutting level is inconclusive, or in the context of a clinical trial, consideration should be
given to including two additional cutting levels at 200 mm intervals (typical focus diameter is <50 μm)
in order to increase the surface area
C/D 37 8.2 (2.0) 92
4 Care should be given to preparation of paraffin blocks, with smaller glands set higher to allow
midspecimen sampling during cutting
D 38 7.5 (2.1) 87
5 Histological examination should determine whether there is FLS present. Attribution of FLS, or possible
FLS, should be followed by calculation of a focus score
B 39 8.8 (1.4) 95
6 The extent (absent, mild, moderate, severe) of atrophy, fibrosis, duct dilatation and non-specific
chronic sialadenitis, in addition to the presence or absence of FLS, should be reported
C 39 8.5 (1.7) 92
7 Calculation of the focus score should include the whole of the glandular surface area in the
denominator, to avoid introduction of bias
D 39 8.3 (1.6) 95
8 The presence or absence of germinal centre-like structures and lymphoepithelial lesions should be
reported
C 39 9.5 (1.0) 97
Guidance relevant to clinical trials
9 The Focus score should be recorded, and the area of individual foci should also be summed and
divided by glandular area to give a more quantitative indication of the extent of glandular infiltration
C 38 7.5 (2.5) 76
10 Once FLS has been confirmed, all foci should be included in the Focus score and in area of foci
calculations, even when adjacent to abnormal acini or ducts, to avoid introduction of bias
D 38 7.3 (2.6) 76
11 Staining for CD3, CD20 and CD21 should be included, and the presence of germinal centre-like
structures should be reported as the proportion of foci with both T/B-cell segregation and follicular
dendritic cell networks. Consideration should be given to reporting the mean B/T cell ratio in foci
C/D 38 8.1 (2.0) 89
12 Scoring should be undertaken by two trained observers who have reviewed a reference slide set, and
with reporting of intraobserver and interobserver variability
D 38 8.9 (1.9) 95
13 Samples should be scored blind to subject and order D 36 8.8 (2.1) 94
14 High-resolution image morphometry of each sample should be stored D 38 8.2 (2.0) 89
15 Given the stable or slowly progressive nature of the histological features, baseline biopsies may be
substituted with prior biopsies to reduce the number of biopsies required. However, given the limited
evidence available, these should have been acquired no longer than 1 year prior to baseline
C 38 7.8 (2.0) 87
16 The optimal period of time for rebiopsy has not been established and will depend on the agent
employed.
D 39 8.3 (1.6) 92
The level of agreement (0–10 scale) among participants is also shown, represented by mean scores and the percentage of respondents who scored the point ≥6/10.
FLS, focal lymphocytic sialadenitis.
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would be expected in all,25 and this combined approach would
avoid the recently highlighted risk of overestimating GCs if
relying on CD21 alone.26 27
Staining for CD3 and CD20 will also allow calculation of the
B/T cell ratio in foci (point 11). While this alone would be
insufﬁcient to indicate the degree of segregation, it can be
readily measured with digital recognition software.
Additional parameters for clinical trials
Although some workshop participants were strong advocates of
measuring the proportion of IgA and IgG plasma cells, this did
not receive sufﬁcient support (mean 6.6; 65% ≥6). Some
evidence suggests that the IgA:IgG plasma cell ratio may have
diagnostic utility, based on the assumption that IgA plasma cells
are normal within the gland (producing secretory IgA) with the
role of IgG plasma cells being unclear,28–31 but arising as a con-
sequence of chronic inﬂammation.32 However, more back-
ground work is required to understand its diagnostic utility and
biomarker potential.
Glandular epithelial cell human leukocyte antigen class II
expression appears directly related to local T-cell activation and
interferon-γ production, and might therefore function as a bio-
marker.33 34 However, again there was insufﬁcient support for
measuring this routinely (mean 6.3; 65% ≥6).
Reporting standards for clinical trials
We recommend that clinical trials using the FS have two obser-
vers who report their interobserver variability (point 12) and
who score samples blind to subject and chronological order
(point 13). Ideally, high-resolution image morphometry of each
sample should be stored to facilitate future comparative studies
(point 14).
Timing of biopsy and placebo groups in clinical trials
It was agreed that pre-existing diagnostic biopsies could be sub-
stituted for baseline biopsies, provided that sufﬁcient material of
acceptable quality was available (point 15). Remarkably, little
data exist on the natural history of histopathological changes in
PSS.7 Therefore, the 1-year cut-off proposed is arbitrary. An
optimal period for rebiopsy has not been determined and may
depend on the agent studied (point 16). A 6-month timeframe
seems reasonable with 3 months being a minimum.
Despite this apparent stability, little is known about variation
in scores with repeat sampling, and so it was proposed to retain
placebo groups even when histology was the primary outcome,
until further experience with heterogeneity of sampling was
available. Overall, there was strong support for this, with scores
close to the deﬁned agreement (mean 6.8 and 74% rating ≥6).
However, a number of responses were strongly negative. Ethical
concerns were raised about performing repeat biopsies on
patients treated with placebo. Furthermore, it was argued that
even in the absence of a placebo group, an improvement in
biopsy scores in a small early phase study would still provide a
positive go/no-go decision and justify further work.
Patient perspective on biopsies in clinical trials
Our patient partners felt that two biopsies over a 12-week
period would be acceptable, although the rationale and objec-
tives should be clearly explained and feedback of the results
would be valued. The ability to use pre-existing samples where
available was considered important.
Agenda for future work
▸ Development of a web-based reference slide set.
▸ Establish variability of assessments over short time frames
using placebo arms of clinical trials. Using these data deter-
mine a minimum number of subjects and minimum detect-
able difference.
▸ Establish optimal glandular surface area requirements/
number of LSGs.
▸ Multicentre study of interobserver variability
▸ Further comparative work between parotid and LSG
biopsies.
▸ Agreement on immunohistochemistry staining protocols, par-
ticularly regarding identiﬁcation of GCs.
Figure 1 Box plot of the 16 agreed points (table 1) on the vertical
axis and level of agreement (0–10) on the horizontal axis. The dashed
line shows the predeﬁned cut-off for agreement. Boxes indicate ﬁrst
and third quartiles with the internal line indicating the median.
Whiskers indicate the minimum and maximum scores given except
when considered outliers, whereas circles indicate outliers (≤1st
quartile–1.5×IQR) and stars far outliers (≤1st quartile–3×IQR).
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▸ Future application of these assessments in ‘positive’ clinical
trials is required to establish discriminant validity.
▸ Revision of this guidance will be undertaken when signiﬁcant
new data are available from the above studies.
▸ Further work on the natural history of FLS in PSS and the
potential biomarker role of IgA, IgG and IgM plasma cells
would be desirable.
▸ Importantly, the patient perspective will be further studied
and morbidity data collected.
DISCUSSION
Standardising histopathological assessment in PSS is an import-
ant objective for routine diagnosis and for clinical trials, to
ensure homogeneity of study populations, and improve reliabil-
ity of assessments and comparability between studies. Extensive
work on this topic has been performed by the members of the
SICCA group.14
Despite so many years of use, however, there remains consid-
erable lack of data regarding the natural history of the histo-
pathological changes associated with PSS, the test reliability or
repeatability and interobserver variability.7 Therefore, the princi-
pal weakness of our report is its dependence on expert opinion.
While this might be a barrier to implementation, we hope that
the points in this report might facilitate communication between
histopathologists and physicians caring for patients.
Furthermore, in the process we have identiﬁed a number of
areas where the evidence base is weak and hope that this will
stimulate further research.
It seems probable that, given the scattered nature of foci, the
reliability of the test would improve in line with increasing
surface area examined, particularly with a lower FS and with
fewer ducts in the sample. However, an optimum surface area
which balances FS reliability with practicality has yet to be
determined. We have recommended obtaining four glands,
although the minimum of 8 mm2 surface area may often be
achieved with two to three glands. However, some glands may
be atrophic or damaged and the material obtained should be
sufﬁcient to overcome these limitations and achieve a valid
result. The surface area examined should be reported to aid the
clinician in their interpretation and for transparency in clinical
trial reports. A single study has demonstrated an increase in
cutting levels to be useful for categorising patients with border-
line FS,35 although, arguably, increasing the number of glands
should be prioritised over the number of cutting levels. If mul-
tiple cutting levels are employed in a clinical trial setting, this
should be protocolised, with scoring based on cumulative
number of foci and glandular area across all slides, to avoid
introduction of bias by selecting the ‘best’ slide. This latter con-
sideration is less relevant for routine diagnosis, where an inter-
pretation may be made based on the clearest level diagnostically,
or a cumulative FS in case of insufﬁcient surface area. We have
suggested that additional cutting levels are done at 200 mm
intervals, as this has been used in the referenced study, although
further work would be required to deﬁne optimal intervals.
We have sought to clarify the issues we identiﬁed with the
determination of FLS and FS calculation. For clinical trials we
have also recommended a focus area calculation. One study
found this correlated better with clinical and autoantibody para-
meters than the FS.36 Measurement of inﬁltrated area avoids
difﬁculties in determining whether to count partially conﬂuent
foci as one or two, and remove the arbitrary ‘ceiling’ score in
case of more widespread conﬂuence. Furthermore, it is not
Figure 2 (A) Microphotograph
illustrating salivary gland biopsy
obtained from a patient with primary
Sjögren’s syndrome, stained with H&E.
(B) Image analysis applied to
macrosection showing delineation of
glandular tissue in red. Focus score is
calculated by counting the number of
foci, whose area is delineated within
the black lines, dividing by the whole
glandular surface area in mm2 and
multiplying by 4 to give the number of
foci per 4 mm2 over the whole
glandular area. In this example, the
glandular surface delineated includes
interspersed atrophic areas but
excludes any attached epithelial or
connective tissue. The measured
glandular area is 20.89 mm2 and there
are 8 foci giving a focus score of 1.53.
(C) Microphotograph illustrating
salivary gland biopsy obtained from a
patient with diagnosis of primary
Sjögren’s syndrome that presents a
large area of ﬁbrosis and parenchymal
atrophy, alongside areas of focal
lymphocytic sialadenitis (original
magniﬁcation ×20).
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unreasonable to expect that where foci are large, a signiﬁcant
reduction in area may occur following therapy despite the
number of foci not being reduced, therefore, affording greater
sensitivity.6 Foci are three-dimensional structures, and so the
area of an individual focus will vary depending on the level at
which it is sectioned. This issue could be minimised by either (i)
ensuring sufﬁcient glandular surface area is examined and (ii)
taking more than one cutting level to avoid bias in the analysis.
There was a strong desire for further guidance on identiﬁca-
tion of GCs. Progressive organisation of foci into lymphoid-like
structures is likely to have pathological consequences and func-
tion may occur without the fully formed appearance on H&E
that can be seen in secondary lymphoid organs. In secondary
lymphoid organs, areas of lighter staining often characterised by
a rounded appearance are easily distinguished within the denser
follicular area. Within these, a light and dark zone segregation is
often also visible. The dark zone is the area of centroblast prolif-
eration and the light zone is inhabited by centrocytes, T follicu-
lar helper cells and FDCs (whose large dendritic-like cytoplasm
is responsible for the lighter staining with H&E). In LSGs, the
detection of such structures is more challenging than in lymph
nodes and GCs are often only appreciable with H&E as areas of
lighter staining within the follicular area without the classical
dark/light zone segregation. The varying prevalence (18%–
59%)37 reported may reﬂect this difﬁculty and the consequent
threshold for identiﬁcation, alongside the differences in cohorts.
This is important to clarify given the discordant data on the
prognostic value of GCs for later lymphoma development.3 4 38
For the purpose of trials we have suggested additional immunos-
taining to study the organisation of foci. Other markers could
be proposed, such as BCL-6 for GC detection,26 and may be
appropriate depending on the study and agent proposed.
Activation-induced cytidine deaminase (AID) is expressed if the
GCs are functional but accurate staining for this is technically
challenging.39
We have focused primarily on LSG tissue. The presence of
LESA is more commonly observed in parotid tissue than in
LSGs,40 with lymphoma development also occurring more often
in the former. While this might be a consideration for the site
of biopsy, the majority of centres still rely on LSGs due to the
ease, familiarity and acceptance of this approach.
Extensive work on measurement of radiographic progression
in rheumatoid arthritis (RA) has shown that inclusion of >1
reader reduces measurement error, and may allow smaller group
sizes. Two readers is a good balance between accuracy and feasi-
bility, and reader training is essential.41 We have extrapolated
this to FS assessment in PSS. There has also been debate in the
RA literature about whether sequential radiographs from the
same patient should be scored together, and whether this should
be done with knowledge of the chronological order.41 42 As dif-
ferent glands are being sampled with LSG biopsy, this latter con-
sideration is less relevant.
Further evaluation of alternative biomarkers to biopsy should
be encouraged, including imaging modalities, salivary
proteomics and peripheral blood immunophenotyping.43–47
Imaging would not provide biological proof of mechanism
however, or mechanistic understanding in the context of a
failed study.
In summary, we have provided a series of recommendations
relating to the use of salivary gland histopathology in the diag-
nosis of PSS and in clinical trials, as a step towards the import-
ant objective of standardisation.
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Figure 3 (A–H) Sequential sections illustrating inﬂammatory
inﬁltrates in the salivary glands of patients with primary Sjögren’s
syndrome stained by H&E (A, C, E), CD3 (brown in B), CD20 (pink in B
and brown in G) and CD21 (brown in D, F and H). (A and B) Sequential
section illustrating segregation in T and B cells in large periductal
inﬁltrate in absence of germinal centre (GC). (C and D) Evident GC in
H&E stained section conﬁrmed by CD21 staining on sequential section.
(E and F) Small CD21+ cluster of follicular dendritic cells (FDCs) in
sequential section of a large aggregate with absence of obvious GC
features at the H&E staining. (G and H) Large CD20+ inﬁltrate with
obvious lymphoepithelial lesions (inset) and the presence of CD21+
FDC networks at the sequential section.
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